Galapagos to Fund Half of Gilead's $1.675B Ouro Acquisition for Autoimmune Drug Collaboration, Gains $500M Cash Flexibility
summarizeSummary
Galapagos and Gilead are in advanced discussions to form a strategic collaboration around Ouro Medicines' clinical-stage T cell engager program (OM336) for autoimmune diseases, following Gilead's definitive agreement to acquire Ouro for $1.675 billion upfront cash and up to $500 million in contingent milestones. Under the proposed terms, Galapagos would contribute 50% of the upfront and milestone payments for the Ouro acquisition, absorb Ouro's operating assets and employees, and share development costs for OM336, with Gilead retaining global commercialization rights (ex-Greater China) and paying Galapagos 20-23% royalties on net sales. Critically, the legacy Option License and Collaboration Agreement (OLCA) between Galapagos and Gilead will be amended, granting Galapagos the flexibility to use up to $500 million of its current cash freely, including up to $150 million for potential share repurchases. This represents a highly material strategic and financial development for Galapagos, providing access to a promising asset while significantly enhancing its capital allocation flexibility. Investors will be watching for the finalization of these collaboration terms and further updates on the OM336 clinical program.
At the time of this announcement, GLPG was trading at $32.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $22.59 to $37.78. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.